General MedicationsSUBCUTANEOUSGeneric

FONDAPARINUX SODIUM

Standard Dose

5MG/0.4ML (5MG/0.4ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview FONDAPARINUX SODIUM is listed in Drugs@FDA under application 216493 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FONDAPARINUX SODIUM Form and strength SOLUTION;SUBCUTANEOUS - 5MG/0.4ML (5MG/0.4ML) Sponsor HANGZHOU ZHONGMEI Submission history Latest submission status date: 2024-08-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview FONDAPARINUX SODIUM is listed in Drugs@FDA under application 216493 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FONDAPARINUX SODIUM Form and strength SOLUTION;SUBCUTANEOUS - 5MG/0.4ML (5MG/0.4ML) Sponsor HANGZHOU ZHONGMEI Submission history Latest submission status date: 2024-08-19 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.